Intronn is known for developing and patenting spliceosome-mediated RNA trans-splicing (SMaRT) technology, a new approach to genetic medicine. SMaRT RNA therapy uses gene therapy vectors to deliver proprietary RNA molecules, known as pre-trans-splicing molecules (PTMs), that can either correct defective gene sequences or provide a new function to a gene.
Dr Riku Rautsola, president and CEO of VIRxSYS said: “We are excited to be expanding the infrastructure for our pipeline of therapies, which we believe holds great promise to alleviate human suffering from terrible diseases. Adding the SMaRT RNA platform to our lentiviral vector delivery platform will help us build VIRxSYS into the driving force behind the next generation of gene therapy.”